Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 4, 24 | -0.62 Increased by +1.59% | -0.66 Increased by +6.06% |
| Feb 29, 24 | -0.64 Decreased by -12.28% | -0.76 Increased by +15.79% |
| Nov 8, 23 | -0.73 Decreased by -28.07% | -0.77 Increased by +5.19% |
| Aug 9, 23 | -0.72 Decreased by -30.91% | -0.70 Decreased by -2.86% |
| May 9, 23 | -0.63 Decreased by -80.00% | -0.62 Decreased by -1.61% |
| Mar 1, 23 | -0.57 Decreased by -18.75% | -0.58 Increased by +1.72% |
| Nov 8, 22 | -0.57 Decreased by -58.33% | -0.52 Decreased by -9.62% |
| Aug 9, 22 | -0.55 Decreased by -7.84% | -0.48 Decreased by -14.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by -100.00% | -48.46 M Decreased by -30.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -47.46 M Decreased by -52.32% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -41.73 M Decreased by -112.14% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 8.77 K Decreased by -99.77% | -37.40 M Decreased by -46.28% | Decreased by -426.59 K% Decreased by -62.26 K% |
| Sep 30, 22 | 132.00 K Decreased by -98.38% | -37.15 M Decreased by -140.53% | Decreased by -28.14 K% Decreased by -14.70 K% |
| Jun 30, 22 | 536.00 K Decreased by -75.83% | -31.16 M Decreased by -40.93% | Decreased by -5.81 K% Decreased by -483.17% |
| Mar 31, 22 | 8.77 M Increased by +101.15% | -19.67 M Decreased by -24.78% | Decreased by -224.39% Increased by +37.97% |
| Dec 31, 21 | 3.74 M Decreased by -27.44% | -25.56 M Decreased by -107.45% | Decreased by -684.08% Decreased by -185.89% |